Shots:
- The US FDA has granted clearance to initiate P-I/II trial of BriaCell‘s Bria-BRES+ for the treatment of metastatic breast cancer
- At AACR, the preclinical data showed that Bria-BRES+ activated adaptive & innate immunity, incl. naïve T cells, dendritic cells, & NK cells, potentially enhancing efficacy & preventing immune escape in metastatic breast cancer
- Bria-BRES+ builds on its Bria-OTS breast cancer clinical program, where the first patient with heavily pretreated metastatic breast cancer achieved complete & sustained resolution of a lung metastasis after 4 doses of single-agent Bria-OTS, with the response maintained through 11mos. & 17 treatment cycles
Ref: Globenewswire | Image: BriaCell | Press Release
Related News: BriaCell Reveals P-II Trial Data of Bria-IMT Regimen for Metastatic Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
